On Monday, Roche Holding AG (RHHBY) completed its purchase of Carmot Therapeutics Inc. The acquisition involved buying all outstanding shares and options of Carmot for $2.7 billion.
Additionally, Carmot's equity holders may receive up to $400 million based on the fulfillment of specific milestones.
This acquisition grants Roche access to Carmot's current R&D portfolio, including clinical and pre-clinical assets, as well as exclusive rights to Carmot's Chemotype Evolution discovery platform in metabolism. This move is set to bolster Roche's R&D endeavors and portfolio in the realms of cardiovascular and metabolic diseases.
Following the completion of the acquisition, Carmot and its employees will become part of the Roche Group under the Pharmaceuticals Division.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.